<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="2416" end="2421" sStart="2328" offset="88" sid="r7.1.use.v.0699" wn="1" wnkey="use%2:34:01::" text="The appropriateness of combining results from individual studies was examined using the Wald ? 2for statistical homogeneity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="10177" end="10185" sStart="null" offset="11" sid="r8.suggest.v.0288" wn="3" wnkey="suggest%2:32:02::" text="This study suggests that the first-line drug therapy for patients diagnosed with gastric ulcer should be a PPI, in preference to an H2 antagonist." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="2935" end="2946" sStart="null" offset="118" sid="r11.recommend.v.0447" wn="1" wnkey="recommend%2:32:01::" text="Overall healing rates of PPIs at four and eight weeks were estimated by pooling the rates for the recommended daily doses: 30 mg/d for lansoprazole, 20 mg/d for omeprazole, 40 mg/d for pantoprazole." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-230X-2-17.anc" start="1448" end="1453" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Currently, five PPIs are marketed: rabeprazole, omeprazole, esomeprazole, lansoprazole and pantoprazole, each with a different pharmacokinetic profile, tissue selectivity, binding specificity and potential to interact with the cytochrome P450 enzyme system [ 8 9 10 ] . For example, rabeprazole and esomeprazole achieve more &lt;b&gt;rapid&lt;/b&gt; and profound inhibition of acid secretion than do older agents [ 10 ] . It is unclear, however, if these pharmacologic differences lead to distinctions in the clinical efficacy of healing gastric ulcers and controlling ulcer symptoms." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-230X-2-17.anc" start="1448" end="1453" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Currently, five PPIs are marketed: rabeprazole, omeprazole, esomeprazole, lansoprazole and pantoprazole, each with a different pharmacokinetic profile, tissue selectivity, binding specificity and potential to interact with the cytochrome P450 enzyme system [ 8 9 10 ] . For example, rabeprazole and esomeprazole achieve more &lt;b&gt;rapid&lt;/b&gt; and profound inhibition of acid secretion than do older agents [ 10 ] . It is unclear, however, if these pharmacologic differences lead to distinctions in the clinical efficacy of healing gastric ulcers and controlling ulcer symptoms." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="4032" end="4036" sStart="null" offset="114" sid="r9.full.j.0712" wn="3" wnkey="full%5:00:00:complete:00" text="To investigate the possible consequences of including abstracts for which we could not obtain full reports, we excluded these data in secondary analyses." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="7461" end="7466" sStart="null" offset="202" sid="r10.find.v.0560" wn="4" wnkey="find%2:32:00::" text="This is consistent with the results obtained for treatment with PPIs when compared to ranitidine for both duodenal ulcers and gastro esophageal reflux disease [ 2 28 ] . We also found that, there is some evidence of an advantage to prescribing two of the newer PPIs (lansoprazole or pantoprazole) compared to omeprazole for gastric ulcer, since there was a 15% increase in healing rates at 4 weeks." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="9562" end="9573" sStart="null" offset="158" sid="r11.combination.n.0902" wn="1" wnkey="combination%1:14:00::" text="More research into maintenance therapy is clearly required, because the relative long-term efficacy of different treatments, particularly the combination of PPIs with antibiotics, and the effect of dose variation on the relapse and complications from gastric ulcers is not well studied." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="6981" end="6988" sStart="null" offset="7" sid="null" wn="1" wnkey="absence%1:26:00::" text="In the absence of active treatment, the majority of patients continued to have a gastric ulcer at the end of the trial." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="6981" end="6988" sStart="null" offset="7" sid="null" wn="1" wnkey="absence%1:26:00::" text="In the absence of active treatment, the majority of patients continued to have a gastric ulcer at the end of the trial." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-2-17.anc" start="6981" end="6988" sStart="null" offset="7" sid="null" wn="1" wnkey="absence%1:26:00::" text="In the absence of active treatment, the majority of patients continued to have a gastric ulcer at the end of the trial." />
  </sentences>
</list>